FDA Approvals Roundup: Pyrukynd and Solosec

FDA Approvals Roundup: Pyrukynd and Solosec

Source: 
RAPS.org
snippet: 

A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).

New approvals
Pyrukynd cleared for hemolytic anemia in adults with rare genetic disorder
Agios Pharmaceuticals’ Pyrukynd (mitapivat; tablets) has been approved for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare genetic disorder that causes the destruction of red blood cells, leading to anemia.